Austin Murtagh | Stern Investor Relations |
Greg Divis | Chief Executive Officer |
Jennifer Gudeman | Senior Vice President-Medical and Clinical Affairs |
Richard Kim | Chief Commercial Officer |
Tom McHugh | Chief Financial Officer |
Chris Howerton | Jefferies |
Adam Evertts | LifeSci Capital |
David Amsellem | Piper Sandler |
Matt Kaplan | Ladenburg Thalmann |
Greetings, and welcome to Avadel Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] It is now my pleasure to introduce Austin Murtagh with Stern Investor Relations. Thank you.
You may begin.
Good morning.